Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Silke Gillessen Sommer, Aurelius Omlin, Gerhardt Attard, Johann S De Bono, Eleni Efstathiou, Karim Fizazi, Susan Halabi, Peter S Nelson, Oliver Sartor, Matthew R Smith, Howard R Soule, Hideyuki Akaza, Tomasz M Beer, Himisha Beltran, Arul M Chinnaiyan, Gedske Daugaard, Ian D Davis, Maria De Santis, Charles G Drake, Rosalind A EelesStefano Fanti, Martin E Gleave, Axel Heidenreich, Maha Hadi Hussain, Nicholas D James, Frederic E Lecouvet, Christopher J Logothetis, Ken Mastris, Sten Nilsson, William K Oh, David Olmos, Anwar Padhani, Christopher Parker, Mark A Rubin, Jack Schalken, Howard I Scher, Avishay Sella, Neal D Shore, Eric J Small, Cora N Sternberg, Hiroyoshi Suzuki, Christopher J Sweeney, Ian F Tannock, Bertrand Tombal

Research output: Contribution to journalArticleOtherpeer-review

232 Citations (Scopus)

Abstract

The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.
Original languageEnglish
Pages (from-to)1589 - 1604
Number of pages16
JournalAnnals of Oncology
Volume26
Issue number8
DOIs
Publication statusPublished - 2015
EventAdvanced Prostate Cancer Consensus Conference 2015 - St Gallen, Switzerland
Duration: 12 Mar 201514 Mar 2015
http://www.prostatecancerconsensus.org/

Keywords

  • Advanced prostate cancer
  • Castration-naïve prostate cancer
  • Castration-resistant prostate cancer
  • Consensus
  • Therapeutics

Cite this